Related Experiment Video
Updated: Aug 18, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics
1HPA Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. keith.foster@hpa.org.uk
Abstract:
Botulinum neurotoxins are used to treat of a range of chronic neuromuscular conditions and, increasingly, conditions involving non-neuromuscular transmission, both cholinergic and non-cholinergic, including chronic pain. However, their clinical use is limited by the potential for adverse effects related to the neuromuscular activity, which results from the selectivity of the toxin for the neuromuscular junction. The elucidation of the structure of the botulinum toxin molecule and its relationship to neurotoxin function has enabled the design of novel molecules incorporating selected aspects of toxin function. This review considers the suitability of engineered neurotoxins as the basis for novel therapeutic proteins and the opportunity of developing analgesics based on these neurotoxins.
Related Concept Videos
Analgesia and Pain Management
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Local Anesthetics: Differential Sensitivity of Nerve Fibers

